2017年EULAR/ACR特发性炎性肌病分类标准在肌炎特异性自身抗体阳性患者中的表现
该研究纳入约翰斯·霍普金斯肌炎中心的524例肌炎特异性自身抗体(MSA)阳性肌炎患者,评估2017年EULAR/ACR分类标准的分类效能。结果显示91%的患者符合该标准,但抗HMGCR和抗PL-7阳性患者常被错误分类,且MSA比EULAR/ACR定义的亚组更能预测临床表型。
要点
- 91%的MSA阳性肌炎患者符合EULAR/ACR分类标准。
- 抗HMGCR和抗PL-7阳性患者常被错误归类为无肌炎。
- MSA对临床表型的预测能力优于EULAR/ACR分类亚组。
核心结论
- EULAR/ACR标准可分类91%的MSA阳性肌炎患者,但抗HMGCR、抗SRP和抗PL-7亚组常被错误分类。
- 在MSA阳性肌炎患者中,自身抗体预测临床表型的能力优于EULAR/ACR定义的肌炎亚组。
- 研究提示修订肌炎分类方案时需纳入MSA。
研究设计与样本
- 研究纳入来自约翰斯·霍普金斯肌炎中心的524例MSA阳性肌炎患者,每位患者均按EULAR/ACR分类标准进行分类。
- 采用混合数据因子分析(FAMD)总结患者表型,并在线性回归模型中应用AIC和BIC比较MSA与EULAR/ACR分类亚组预测表型的能力。
主要发现
- 总体91%的MSA阳性患者符合EULAR/ACR标准被分类为肌炎。
- 20%的抗HMGCR阳性患者和50%的抗PL-7阳性患者被错误分类为无肌炎。
- 约10%的抗SRP阳性患者和抗HMGCR阳性患者被错误分类为包涵体肌炎。
- FAMD显示每个MSA定义亚组内患者表型相似。
- AIC和BIC分析显示MSA比EULAR/ACR分类亚组更好地预测肌炎表型。
关键数值与推荐
- 91%的MSA阳性患者符合EULAR/ACR分类标准。
- 20%的抗HMGCR阳性患者和50%的抗PL-7阳性患者被错误分类为无肌炎。
- 约10%的抗SRP阳性患者和抗HMGCR阳性患者被错误分类为包涵体肌炎。
临床怎么用
- 对MSA阳性肌炎患者,尤其是抗HMGCR、抗SRP和抗PL-7阳性者,应警惕EULAR/ACR标准可能误分类。
- 临床表型预测和分类评估中应结合MSA信息,而非仅依赖EULAR/ACR分类亚组。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: We undertook this study to 1) determine the sensitivity of the European Alliance of Associations for Rheumatology (EULAR)/American College of Rheumatology (ACR) classification criteria for idiopathic inflammatory myopathies (IIMs) to properly classify myositis-specific autoantibody (MSA)-positive myositis patients, 2) describe the phenotype and muscle involvement over time in different MSA-positive patients, and 3) compare MSA subgroups to EULAR/ACR criteria-defined myositis subgroups for their capacity to predict clinical phenotypes in patients with IIMs. METHODS: The study included 524 MSA-positive myositis patients from the Johns Hopkins Myositis Center. Each patient was classified using the EULAR/ACR classification criteria. Patient phenotypes were summarized using factor analysis of mixed data (FAMD). We compared the ability of MSAs to that of the EULAR/ACR classification subgroups to predict the phenotype of patients by applying the Akaike information criterion (AIC) and the Bayesian information criteria (BIC) to the linear regression models. RESULTS: Overall, 91% of MSA-positive patients met the EULAR/ACR criteria to be classified as having myositis. However, 20% of patients with anti-hydroxymethylglutaryl-coenzyme A reductase (anti-HMGCR) and 50% of patients with anti-PL-7 were incorrectly classified as not having myositis. Furthermore, ~10% of patients with anti-signal recognition particle (anti-SRP) and patients with anti-HMGCR were misclassified as having inclusion body myositis. FAMD demonstrated that patients within each MSA-defined subgroup had similar phenotypes. Application of both the AIC and BIC to the linear regression models revealed that MSAs were better predictors of myositis phenotypes than the subgroups defined by the EULAR/ACR criteria. CONCLUSION: Although the EULAR/ACR criteria successfully classified 91% of MSA-positive myositis patients, certain MSA-defined subgroups, including those with autoantibodies against HMGCR, SRP, and PL-7, are frequently misclassified. In myositis patients with MSAs, autoantibodies outperform the EULAR/ACR-defined myositis subgroups in predicting the clinical phenotypes of patients. These findings underscore the need to include MSAs in a revised myositis classification scheme.
引用
- Casal-Dominguez M, Pinal-Fernandez I, Pak K, et al. Performance of the 2017 European Alliance of Associations for Rheumatology/American College of Rheumatology Classification Criteria for Idiopathic Inflammatory Myopathies in Patients With Myositis-Specific Autoantibodies. Arthritis Rheumatol. 2022. PMID: 34480833. doi:10.1002/art.41964
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。